# AMX0035 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/amx0035

> The FDA approved AMX0035, sponsored by Amylyx Pharmaceuticals, Inc. (AMLX), on Sep 2022 for ALS in adults.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AMX0035 |
| Codes | AMX0035 |
| Sponsor | Amylyx Pharmaceuticals, Inc. (AMLX) https://sec-api.dev/companies/amlx/catalysts |
| Indications | als in adults, Progressive Supranuclear Palsy |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### Sep 2022: FDA approval

- Status: completed, approved. Date confidence: month. Indication: ALS in adults.
- First seen 2025-03-04, last confirmed 2025-03-04.
- SEC Form 10-K (accession 0000950170-25-031309): "In September 2022, AMX0035 received approval as RELYVRIO by the FDA for the treatment of ALS in adults, and the Company launched RELYVRIO in the U.S. in October 2022." https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-04, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0001193125-25-174948): "In December 2023, we initiated the Phase 2b/3 ORION (NCT06122662) clinical trial, a global, randomized, double-blind, placebo-controlled trial of AMX0035 for the treatment of PSP." https://www.sec.gov/Archives/edgar/data/1658551/000119312525174948/amlx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-066363): "In December 2023, we initiated the Phase 2b/3 ORION (NCT06122662) clinical trial, a global, randomized, double-blind, placebo-controlled trial of AMX0035 for the treatment of PSP." https://www.sec.gov/Archives/edgar/data/1658551/000095017025066363/amlx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-031309): "In December 2023, we initiated the Phase 2b/3 ORION (NCT06122662) clinical trial, a global, randomized, double-blind, placebo-controlled trial of AMX0035 for the treatment of PSP." https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm

### Apr 2024: topline data readout

- Status: completed, missed. Date confidence: month. Stage: 3.
- First seen 2025-03-04, last confirmed 2025-03-04.
- SEC Form 10-K (accession 0000950170-25-031309): "In April 2024, the Company announced that it had started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO and ALBRIOZA (AMX0035) for ALS and remove the product from the market based on topline results from the global Phase 3 PHOENIX trial, which did not meet its prespecified primary and secondary endpoints." https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm

### Oct 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-03-04, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448529): "In October 2024, we announced positive topline data from the Phase 2 open-label HELIOS (NCT05676034) clinical trial of AMX0035 in 12 adults living with Wolfram syndrome." https://www.sec.gov/Archives/edgar/data/1658551/000119312526448529/amlx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-336682): "In October 2024, we announced positive topline data from the Phase 2 open-label HELIOS (NCT05676034) clinical trial of AMX0035 in 12 adults living with Wolfram syndrome." https://www.sec.gov/Archives/edgar/data/1658551/000119312526336682/amlx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-210292): "In October 2024, we announced positive topline data from the Phase 2 open-label HELIOS (NCT05676034) clinical trial of AMX0035 in 12 adults living with Wolfram syndrome." https://www.sec.gov/Archives/edgar/data/1658551/000119312526210292/amlx-20260331.htm
- SEC Form 10-Q (accession 0001193125-25-268059): "In October 2024, we announced positive topline data, including the primary efficacy outcome of the trial, from the Phase 2 open-label HELIOS clinical trial of AMX0035 in 12 adults living with Wolfram syndrome, and in May 2025, we announced positive long-term data from the HELIOS trial of AMX0035 in Wolfram syndrome through Week 48." https://www.sec.gov/Archives/edgar/data/1658551/000119312525268059/amlx-20250930.htm
- SEC prospectus (424B) (accession 0001193125-25-200144): "In October 2024, we announced positive topline data, including the primary efficacy outcome of the trial, from the Phase 2 open-label HELIOS clinical trial of AMX0035 in 12 adults living with Wolfram syndrome, and in May 2025, we announced positive long-term data from the HELIOS trial of AMX0035 in Wolfram syndrome through Week 48." https://www.sec.gov/Archives/edgar/data/1658551/000119312525200144/d27062d424b5.htm
- SEC Form 10-Q (accession 0001193125-25-174948): "In October 2024, we announced positive topline data, including the primary efficacy outcome of the trial, from the Phase 2 open-label HELIOS clinical trial of AMX0035 in 12 adults living with Wolfram syndrome, and in May 2025, we announced positive long-term data from the HELIOS trial of AMX0035 in Wolfram syndrome through Week 48." https://www.sec.gov/Archives/edgar/data/1658551/000119312525174948/amlx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-066363): "In October 2024, we announced positive topline data from the Phase 2 open-label HELIOS clinical trial of AMX0035 in 12 adults living with Wolfram syndrome." https://www.sec.gov/Archives/edgar/data/1658551/000095017025066363/amlx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-031309): "In October 2024, we announced positive topline data from the Phase 2 open-label HELIOS clinical trial of AMX0035 in 12 adults living with Wolfram syndrome." https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm
- SEC Form 10-K (accession 0001193125-26-086645): "In October 2024, we announced positive topline data from HELIOS at week 24." https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/amlx-20251231.htm

### Q3 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-03-04, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0001193125-25-174948): "Efficacy and safety data from an unblinded interim analysis of the Phase 2b portion of the Phase 2b/3 ORION trial of AMX0035 in PSP is anticipated in the third quarter of 2025, which will be used to inform a go/no-go decision on the Phase 3 portion of the trial." https://www.sec.gov/Archives/edgar/data/1658551/000119312525174948/amlx-20250630.htm
- SEC Form 10-K (accession 0000950170-25-031309): "Data from an unblinded interim analysis of the Phase 2b portion of the Phase 2b/3 ORION trial of AMX0035 in PSP is anticipated in the third quarter of 2025, which will be used to inform a go/no-go decision on the Phase 3 portion of the trial." https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-031303): "This year, we anticipate Week 48 data from our AMX0035 program in Wolfram syndrome, interim analysis data from our AMX0035 program in PSP, and early cohort data from our AMX0114 program in ALS," said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx." https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/amlx-ex99_1.htm

### September 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06122662 (AMX0035 and Progressive Supranuclear Palsy): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Amylyx Pharmaceuticals Inc.." https://clinicaltrials.gov/study/NCT06122662

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-06, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268043): "Separately, we are advancing the clinical development of AMX0035 in Wolfram syndrome, and pending alignment with the FDA, we plan to initiate a focused, pivotal Phase 3 clinical trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268043): "Amylyx is advancing the clinical development of AMX0035 in Wolfram syndrome and, pending alignment with the FDA, planning to initiate a focused, pivotal Phase 3 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-268059): "We are advancing the clinical development of AMX0035 in Wolfram syndrome and, pending alignment with the FDA, plan to initiate a focused, pivotal Phase 3 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1658551/000119312525268059/amlx-20250930.htm

## Same indication

- [NIO752](https://sec-api.dev/pdufa/nio752) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/amx0035.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMX0035 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/amx0035

```bibtex
@misc{secapidev_pdufa_amx0035_20261116,
  title        = {AMX0035 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/amx0035}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_amx0035_20261116","title":"AMX0035 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/amx0035","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
